Alliqua BioMedical, Inc. (NASDAQ:ALQA) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
On April 27, 2018, Alliqua BioMedical, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, the following three proposals were submitted to a vote of the Company’s stockholders:
| (1) | A proposal to approve the Asset Purchase Agreement, dated January 5, 2018 (the “Asset Purchase Agreement”), providing for the sale of our advanced biologic wound care business, including the Company’s Biovance and Interfyl product lines and MIST Therapy and other therapeutic ultrasound products, which may be deemed to be a sale of all, or substantially all, of the Company’s assets to Celularity Inc. (the “Buyer”) on the terms and subject to the conditions set forth in the Asset Purchase Agreement (the “Asset Sale”), and the other transactions contemplated by the Asset Purchase Agreement (the “Asset Sale Proposal”). |
| (2) | A proposal to approve, on an advisory, non-binding basis, certain compensation that has, will or may be paid or become payable to the Company’s named executive officers in connection with the asset sale (the “Advisory Proposal”). |
| (3) | A proposal to approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of any of the foregoing proposals (the “Adjournment Proposal”). |
For more information about the foregoing proposals, see the Company’s definitive proxy statement filed with the Securities and Exchange Commission on March 30, 2018, the relevant portions of which are incorporated herein by reference. The number of votes cast for and against and the number of abstentions with respect to each matter voted upon are set forth below.
| (1) | Approval of the Asset Sale Proposal: |
| Votes For | Votes Against | Votes Abstaining |
| 2,646,460 | 65,317 | 51,042 |
| (2) | Approval of the Advisory Proposal: |
| Votes For | Votes Against | Votes Abstaining |
| 2,540,164 | 172,300 | 50,355 |
| (3) | Approval of the Adjournment Proposal: |
| Votes For | Votes Against | Votes Abstaining |
| 2,664,411 | 79,100 | 19,308 |
The results reported above are final voting results. No other matters were considered or voted upon at the meeting.
About Alliqua BioMedical, Inc. (NASDAQ:ALQA)
Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers TheraBond 3D Antimicrobial Barrier Systems and SilverSeal.
